Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) has been given an average rating of “Moderate Buy” by the ten brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.10.
ROIV has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, June 18th. Piper Sandler boosted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Monday, August 19th.
Get Our Latest Stock Report on ROIV
Institutional Investors Weigh In On Roivant Sciences
Roivant Sciences Stock Performance
Shares of ROIV opened at $12.23 on Friday. The company has a 50-day moving average of $11.07 and a two-hundred day moving average of $11.00. The stock has a market cap of $9.03 billion, a price-to-earnings ratio of 2.42 and a beta of 1.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24. Roivant Sciences has a one year low of $8.24 and a one year high of $13.24.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. The company’s quarterly revenue was up 155.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.38) EPS. On average, equities research analysts expect that Roivant Sciences will post -1.12 earnings per share for the current year.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
- Five stocks we like better than Roivant Sciences
- How Technical Indicators Can Help You Find Oversold Stocks
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.